Kanada - Ingliż - Health Canada

nuron biotech b.v. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm-197 protein - suspension - 10mcg; 15mcg - meningococcal group c oligosaccharide 10mcg; corynebacterium diphtheriae crm-197 protein 15mcg - vaccines

Kanada - Ingliż - Health Canada

pfizer canada ulc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group w-135; meningococcal polysaccharide antigen group y; tetanus toxoid - kit - 5mcg; 5mcg; 5mcg; 5mcg; 44mcg - meningococcal polysaccharide antigen group a 5mcg; meningococcal polysaccharide antigen group c 5mcg; meningococcal polysaccharide antigen group w-135 5mcg; meningococcal polysaccharide antigen group y 5mcg; tetanus toxoid 44mcg - vaccines

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - haemophilus influenza type b polyribose ribitol phosphate,meningococcal polysaccharide group c,tetanus toxoid -

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - conjugate of haemophilus influenzae type b capsular polysaccharide and tetanus toxoid 12,5 ; neisseria meningitidis group c polysaccharides conjugated to tetanus toxoid as a carrier 5 - powder and solvent for solution for injection - haemophilus influenzae type b polysaccharides, conjugated to tetanus toxoid; neisseria meningitidis c, polysaccharides conjugated to tetanus toxoid as a carrier - hemophilus influenzae b, combinations with pertussis and toxoids

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - neisseria meningitidis group c polysaccharides conjugated to tetanus toxoid as a carrier 10 - suspension for injection - 10 µg/0,5 ml - neisseria meningitidis c, polysaccharides conjugated to tetanus toxoid as a carrier - meningococcus c, purified polysaccharides antigen conjugated

Panama - Ingliż - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

pfizer europe ma eeig - neisseria meningitidis serogrupo b fhbp subfamilia a - neisseria meningitidis serogrupo b fhbp subfamilia a....60 mcg. / neisseria meningitidis serogrupo b fhbp subfamilia b....60 mcg.

Filippini - Ingliż - FDA (Food And Drug Administration)

n/a; importer: sanofi pasteur, inc.; distributor: zuellig pharma corporation - meningococcal group a, c, w-135 and y conjugate vaccine - solution for injection (im) - formulation: each dose (0.5 ml) contains: neisseria meningitidis group a polysaccharide* .... 10 mcg neisseria meningitidis group c polysaccharide* .... 10 mcg neisseria meningitidis group y polysaccharide* .... 10 mcg neisseria meningitidis group w-135 polysaccharide* .... 10 mcg *conjugated to tetanus toxoid carrier protein... 55 mcg** **tetanus toxoid quantity is approximate and dependent on the polysaccharide to protein ratio for the conjugates in each formulation

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group a, quantity: 10 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; meningococcal polysaccharide group w135, quantity: 5 microgram; meningococcal polysaccharide group y, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate; water for injections - menveo is indicated for active immunisation of children (from 2 years of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w135 and y. the use of this vaccine should be in accordance with official recommendations.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen (unii: t4gyx3110d) (neisseria meningitidis group a capsular polysaccharide tetanus toxoid conjugate antigen - unii:t4gyx3110d), neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen (unii: zt89e5a103) (neisseria meningitidis group c capsular polysaccharide tetanus toxoid conjugate antigen - unii:zt89e5a103), neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conj - penbraya is indicated for active immunization to prevent invasive disease caused by neisseria meningitidis serogroups a, b, c, w, and y. penbraya is approved for use in individuals 10 through 25 years of age. do not administer penbraya to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of penbraya [see description (11)] .              pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to penbraya during pregnancy. individuals who received penbraya during pregnancy are encouraged to contact, or have their healthcare provider contact, 1-877-390-2953 to enroll in or obtain information about the registry. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are no clinical studi

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - neisseria meningitidis, group b (strain nz98/254) 25ug (as outer membrane vesicles (omv));   - suspension for injection - 25 mcg/0.5ml - active: neisseria meningitidis, group b (strain nz98/254) 25ug (as outer membrane vesicles (omv))   excipient: aluminium hydroxide histidine sodium chloride water for injection